---
title: 'Clinical Daily Summary: What Happened on November 13, 2026'
headline: Melanoma vaccine cuts recurrence-or-death risk by 42% in Phase 3
description: Pelacarsen missed its Phase 3 primary endpoint. The day also brought
  early heart-failure and obesity data, plus longer-term findings in immune disease.
url: https://thebench.bio/news/clinical/2026-11-13
topic: clinical
date: '2026-11-13'
covers:
- '2026-11-13'
date_published: '2026-11-13T12:03:13Z'
date_modified: '2026-11-14T00:02:14Z'
tags:
- Industry
- Clinical
- Software
sources: 12
publisher: TheBench.Bio
---

# Clinical Daily Summary: What Happened on November 13, 2026

**Melanoma vaccine cuts recurrence-or-death risk by 42% in Phase 3**

Pelacarsen missed its Phase 3 primary endpoint. The day also brought early heart-failure and obesity data, plus longer-term findings in immune disease.

## Today in brief

Merck and Moderna’s personalized vaccine, given with pembrolizumab after melanoma surgery, lowered the risk of recurrence or death by 42% versus pembrolizumab alone in a Phase 3 trial. [1] [2] Pelacarsen missed the primary endpoint in the Phase 3 HORIZON trial. [3]

## Melanoma vaccine lowers recurrence-or-death risk by 42%

Merck and Moderna’s intismeran autogene lowered recurrence-or-death risk by 42% when added to pembrolizumab after surgery for high-risk melanoma. [1] [2] In the randomized trial of nearly 1,140 patients, two-year recurrence-free survival was 82% with the combination and 70% with pembrolizumab alone. [1]

The combination also reduced distant metastasis-or-death risk by 38%, with a prespecified analysis finding benefit in earlier- and later-stage disease. [1] [2] Common side effects included fever, injection-site pain and fatigue. Treatment stopped in 16.6% of the combination group and 9.5% of controls. [1] [2]

The results were presented at the European Society for Medical Oncology meeting in October and published in The New England Journal of Medicine. [1] [2] Researchers and company executives said longer survival follow-up and more detailed immune findings are needed to guide treatment decisions and explain the vaccine’s effects. [1] Merck and Moderna are preparing a Food and Drug Administration filing and anticipate possible approval in 2027. [1]

## Pelacarsen misses HORIZON’s primary endpoint

Pelacarsen did not meet the primary endpoint in the Phase 3 HORIZON trial. [3] The drug targets lipoprotein(a), a cardiovascular risk factor. [3]

## Also worth knowing

- Novartis reported sustained symptom improvements through 52 weeks with Rhapsido across three chronic inducible urticaria subtypes, with no new safety signals. The company plans regulatory applications for expanded use. [4]
- Vasa Therapeutics said its early Phase 1c study of VS-041 in heart failure with preserved ejection fraction lowered NT-proBNP and identified serum endotrophin as a possible fibroinflammation marker. Further analyses are expected in early 2027. [5]
- In Vivani Medical’s 20-person Phase 1 study, recipients of its semaglutide implant NPM-139 lost 0.79% of body weight over four weeks. No implant recipients had treatment-related adverse events. [6]
- Wave Life Sciences reported one-year body-composition changes after a single 240 mg dose of WVE-007. Visceral and total fat and waist measurements fell versus placebo while lean mass was maintained. The interim findings have not been peer reviewed. [7]
- Zai Lab said ZL-1503 inhibited an atopic dermatitis-related biomarker by at least 90% at week 12 in healthy volunteers given 200 to 1,000 mg. The study did not assess clinical efficacy. [8]
- In Ionis’s open-label OASISplus extension, hereditary angioedema attack rates after two years were 95% below baseline among 83 participants. Rates among 64 patients who switched from prior prevention therapy were 71% below their previous-treatment baseline. [9]
- In external validation, PERISCOPE models assigned in-hospital death risk correctly in 91% of comparisons, versus about 85% for GRACE 2.0. Researchers said prospective testing is still needed. [10]
- Plozasiran maintained triglyceride-lowering activity alongside GLP-1 receptor agonists. [11]
- Kerendia had similar effects on heart failure events and cardiovascular death across kidney-risk groups in patients with mildly reduced or preserved ejection fraction. [12]

## The day in numbers

- **42%**: Lower recurrence-or-death risk with intismeran autogene plus pembrolizumab versus pembrolizumab alone in resected melanoma. [1] [2]
- **82% vs. 70%**: Two-year recurrence-free survival with the melanoma vaccine combination versus pembrolizumab alone. [1]
- **52 weeks**: Duration of sustained symptom improvements reported with Rhapsido across three chronic inducible urticaria subtypes. [4]
- **91% vs. about 85%**: PERISCOPE versus GRACE 2.0 risk-assignment performance for in-hospital death comparisons in external validation. [10]

## Also published

- [How Inconsistent Screening Shapes Which Oncology Patients Get Flagged for Trials](<https://www.appliedclinicaltrialsonline.com/view/how-inconsistent-screening-shapes-oncology-patients-flagged-trials>), Applied Clinical Trials
- [AHA 2026: Tirzepatide Improves Key Biomarkers in Obesity-Related Heart Failure](<https://www.clinicaltrialsarena.com/analyst-comment/aha-2026-tirzepatide-improves-key-biomarkers-in-obesity-related-heart-failure/>), Clinical Trials Arena
- [AHA26: Novo reveals baseline data for Phase III ARTEMIS trial](<https://www.clinicaltrialsarena.com/analyst-comment/aha-2026-novo-reveals-baseline-data-for-phase-iii-artemis-trial/>), Clinical Trials Arena
- [AHA26: Semaglutide’s real-world CV benefits highlight importance of persistence](<https://www.pharmaceutical-technology.com/analyst-comment/aha26-semaglutides-real-world-cv-benefits-highlight-importance-of-persistence/>), Pharmaceutical Technology
- [AHA26: CRISPR gene editing shows promise in Phase Ib hypertriglyceridaemia trial](<https://www.clinicaltrialsarena.com/analyst-comment/aha26-crispr-gene-editing-shows-promise-in-phase-ib-hypertriglyceridaemia-trial/>), Clinical Trials Arena
- [AHA26: MAR001 highlights potential of ANGPTL4 inhibition for triglyceride lowering](<https://www.clinicaltrialsarena.com/analyst-comment/aha26-mar001-highlights-potential-of-angptl4-inhibition-for-triglyceride-lowering/>), Clinical Trials Arena
- [AMP 2026: Is Human Expertise Limiting AI Diagnostics?](<https://www.insideprecisionmedicine.com/topics/molecular-dx/amp-2026-is-human-expertise-limiting-ai-diagnostics/>), Inside Precision Medicine
- [When Small Protocol Decisions Become Enrollment or Retention Barriers](<https://www.pharmexec.com/view/when-small-protocol-decisions-become-enrollment-or-retention-barriers>), Pharmaceutical Executive
- [Why So Many Patients From Underrepresented Groups Are Never Asked to Join a Trial](<https://www.appliedclinicaltrialsonline.com/view/why-many-patients-underrepresented-groups-never-asked-join-trial>), Applied Clinical Trials
- [How Patients’ Use of AI Impact How Sponsors Communicate with Them](<https://www.pharmexec.com/view/patients-use-ai-impact-how-sponsors-communicate-with-them>), Pharmaceutical Executive

## Sources

1. [Cancer vaccine development gets complicated](<https://www.nature.com/articles/d41573-026-00181-8>), Nature Reviews Drug Discovery, 2026-11-13
2. [Moderna Lays Out Oncology-Driven Growth Plan at 2026 Analyst Day](<https://www.pharmexec.com/view/moderna-oncology-driven-growth-plan-2026-analyst-day>), Pharmaceutical Executive, 2026-11-12
3. [AHA26: Pelacarsen misses primary endpoint in Phase III HORIZON trial](<https://www.clinicaltrialsarena.com/analyst-comment/aha26-pelacarsen-misses-primary-endpoint-in-phase-iii-horizon-trial/>), Clinical Trials Arena, 2026-11-13
4. [Novartis eyes Rhapsido’s broader use on positive urticaria data drop ](<https://www.clinicaltrialsarena.com/news/novartis-eyes-rhapsido-broader-use-positive-urticaria-cindu-data/>), Clinical Trials Arena, 2026-11-13
5. [Vasa’s VS-041 shows positive Phase Ic results in HFpEF trial](<https://www.clinicaltrialsarena.com/news/vasas-vs-041-positive-results-hfpef-trial/>), Clinical Trials Arena, 2026-11-13
6. [Vivani reports encouraging Phase I findings for semaglutide implant](<https://www.clinicaltrialsarena.com/news/vivani-encouraging-findings-npm-139-implant/>), Clinical Trials Arena, 2026-11-13
7. [Wave Reports 1-Year INLIGHT Data for INHBE siRNA WVE-007 in Obesity](<https://www.biopharminternational.com/view/wave-wve-007-inhbe-sirna-inlight-obesity-data>), BioPharm International, 2026-11-13
8. [Zai Lab’s Long-Acting Atopic Dermatitis Bispecific Points to Every-12-Week Dosin](<https://www.biopharminternational.com/view/zai-lab-s-long-acting-atopic-dermatitis-bispecific-points-to-every-12-week-dosin>), BioPharm International, 2026-11-13
9. [Ionis Reports 2-Year Donidalorsen (Dawnzera) Data in HAE Prophylaxis](<https://www.biopharminternational.com/view/ionis-donidalorsen-dawnzera-2-year-oasisplus-hae-data>), BioPharm International, 2026-11-13
10. [AI Model Accurately Predicts Risk for Death After Heart Attack](<https://www.insideprecisionmedicine.com/topics/molecular-dx/ai-model-accurately-predicts-risk-for-death-after-heart-attack/>), Inside Precision Medicine, 2026-11-13
11. [AHA26: Plozasiran maintains TG-lowering efficacy alongside GLP-1RAs](<https://www.clinicaltrialsarena.com/analyst-comment/aha26-plozasiran-maintains-tg-lowering-efficacy-alongside-glp-1ras/>), Clinical Trials Arena, 2026-11-13
12. [AHA26: Kerendia shows efficacy in heart failure across kidney failure risk strata](<https://www.clinicaltrialsarena.com/analyst-comment/aha-26-kerendia-shows-efficacy-heart-failure-across-kidney-failure-risk-strata/>), Clinical Trials Arena, 2026-11-13

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.nature.com/articles/d41573-026-00181-8>
[2]: <https://www.pharmexec.com/view/moderna-oncology-driven-growth-plan-2026-analyst-day>
[3]: <https://www.clinicaltrialsarena.com/analyst-comment/aha26-pelacarsen-misses-primary-endpoint-in-phase-iii-horizon-trial/>
[4]: <https://www.clinicaltrialsarena.com/news/novartis-eyes-rhapsido-broader-use-positive-urticaria-cindu-data/>
[5]: <https://www.clinicaltrialsarena.com/news/vasas-vs-041-positive-results-hfpef-trial/>
[6]: <https://www.clinicaltrialsarena.com/news/vivani-encouraging-findings-npm-139-implant/>
[7]: <https://www.biopharminternational.com/view/wave-wve-007-inhbe-sirna-inlight-obesity-data>
[8]: <https://www.biopharminternational.com/view/zai-lab-s-long-acting-atopic-dermatitis-bispecific-points-to-every-12-week-dosin>
[9]: <https://www.biopharminternational.com/view/ionis-donidalorsen-dawnzera-2-year-oasisplus-hae-data>
[10]: <https://www.insideprecisionmedicine.com/topics/molecular-dx/ai-model-accurately-predicts-risk-for-death-after-heart-attack/>
[11]: <https://www.clinicaltrialsarena.com/analyst-comment/aha26-plozasiran-maintains-tg-lowering-efficacy-alongside-glp-1ras/>
[12]: <https://www.clinicaltrialsarena.com/analyst-comment/aha-26-kerendia-shows-efficacy-heart-failure-across-kidney-failure-risk-strata/>
